Plain-language explainers, news and honest takes on peptides. New posts weekly.
An advisory committee voted in July to recommend six peptides for the compounding list. The vote is not a final decision, and it is not approval.
Lilly's triple-agonist drug has posted some of the largest weight loss numbers ever seen in a phase 3 trial. It is still not approved. Here is what the data says and what comes next.
The FDA advisory vote made headlines, but BPC-157 still sits on the 'do not compound' side. Here is what the list is and what is actually legal right now.
Five peptide sellers got FDA warning letters in August 2026, and the letter means something more specific than most people assume.
A compounding pharmacy recalled glutathione injections over contamination. Here is what happened, and why compounded quality is a real risk with anything you inject.
A plain beginner's guide to semaglutide, tirzepatide, and retatrutide: how they differ, and where each one stands.
Half the peptides you read about are sold 'for research use only.' Here is what that label really means, and why peptide legality is so confusing right now.
In July 2026 an FDA advisory panel recommended adding BPC-157, TB-500 and others to the compounding list, against the agency's own advice. Here is what that does and does not mean.
BPC-157 is one of the most talked-about recovery peptides. Here is what the science shows, what it does not, and the tumor question most sites skip.
A plain-language beginner's guide to what peptides are, why the excitement is real, and where the hype gets ahead of the facts.
Plain-language updates on new research and the shifting rules. No hype, unsubscribe anytime.